Lilly Places Additional Marketing Support Behind Cymbalta For Diabetic Pain
Executive Summary
Lilly is ramping up initiatives behind its selective serotonin and norepinephrine reuptake inhibitor Cymbalta (duloxetine) for the diabetic pain market
You may also be interested in...
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Pfizer's first steps in marketing Lyrica's new indication for fibromyalgia - the first FDA approval for the condition - will be partnering with patient advocacy groups to raise awareness and conduct educational programs
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Pfizer's first steps in marketing Lyrica's new indication for fibromyalgia - the first FDA approval for the condition - will be partnering with patient advocacy groups to raise awareness and conduct educational programs
For Lilly Sales Force The Future Is Now: Reorg Emphasizes Sales Specialists
Lilly is focused on increasing sales team efficiency - not reducing overall headcount - with its "sales force of the future" reorganization